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AbstrAct
Objective Severe vitamin D deficiency is a recognised 
cause of skeletal muscle fatigue and myopathy. The 
aim of this study was to examine whether chronic 
fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is 
associated with altered circulating vitamin D metabolites.
Design Cohort study.
setting UK university hospital, recruiting from April 2014 
to April 2015.
Participants Ninety-two patients with CFS/ME and 94 
age-matched healthy controls (HCs).
Main outcome measures The presence of a significant 
association between CFS/ME, fatigue and vitamin D 
measures.
results No evidence of a deficiency in serum total 25(OH) 
vitamin D (25(OH)D
2 and 25(OH)D3 metabolites) was 
evident in individuals with CFS/ME. Liquid chromatography 
tandem mass spectrometry (LC–MS/MS) analysis revealed 
that total 25(OH)D was significantly higher (p=0.001) 
in serum of patients with CFS/ME compared with HCs 
(60.2 and 47.3 nmol/L, respectively). Analysis of food/
supplement diaries with WinDiets revealed that the higher 
total 25(OH) vitamin D concentrations observed in the CFS/
ME group were associated with increased vitamin D intake 
through use of supplements compared with the control 
group. Analysis of Chalder Fatigue Questionnaire data 
revealed no association between perceived fatigue and 
vitamin D levels.
conclusions Low serum concentrations of total 25(OH)
D do not appear to be a contributing factor to the level of 
fatigue of CFS/ME.
IntrODuctIOn
Chronic fatigue syndrome (CFS), also 
referred to as myalgic encephalomyelitis 
(ME), is a debilitating and complex disease 
characterised by prolonged and disabling 
fatigue.1 Patients with CFS/ME suffer from 
a range of symptoms including headache, 
painful lymph nodes, sore throat, difficulty 
in sleeping or insomnia, poor cognitive func-
tion, muscle/joint pain and postexertional 
malaise. CFS/ME can affect individuals of 
all ages, races and socioeconomic status. 
Prevalence of the disease has been estimated 
between 0.2% and 1%.2–4 Despite the severity 
of CFS/ME and the prevalence of the disease, 
the aetiology and pathophysiology of CFS/ME 
is yet to be determined due to a lack of robust 
evidence within current literature to confirm 
any specific biological abnormalities. Current 
areas of investigation include infection, endo-
crine dysfunction, autonomic nervous system 
imbalance and altered immunity.
Vitamin D regulation has become a leading 
focus of health professionals following its 
implication in health and disease.5–7 Vitamin 
D metabolites are regarded as vital endo-
crine regulators of bone health via their role 
in calcium and phosphate homeostasis.8 9 
Evidence has shown that vitamin D deficiency 
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strengths and limitations of this study
 ► This is the first cross-sectional analysis of vitamin 
D status to be determined in patients with chronic 
fatigue syndrome/myalgic encephalomyelitis (CFS/
ME).
 ► Patients were referred through a single National 
Health Service (NHS) CFS services unit at the Royal 
Liverpool and Broadgreen University NHS trust and 
diagnosed with CFS/ME using the National Institute 
for Health and Care Excellence guidelines ensuring 
diagnostic uniformity.
 ► Serum 25-hydroxyvitamin D, the main marker 
of vitamin D status, was determined using liquid 
chromatography tandem mass spectrometry and 
comprehensive dietary/supplement analyses were 
undertaken to support vitamin D serum data.
 ► Recruitment included a broad spectrum of 
ambulatory patients with CFS/ME, age and sex 
matched to health controls, but excluded the 
severest, non-ambulatory patients with CFS/ME.
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(25(OH)D<30 nmol/L)10 is associated with numerous 
adverse health outcomes, including risk of rickets in chil-
dren or osteomalacia in adults, increased risk of fractures, 
falls, infectious disease, type 1 and type 2 diabetes, cancer, 
autoimmune disease, multiple sclerosis, hypertension and 
heart disease.11 Since the identification of the vitamin D 
receptor in almost all tissues of the human body including 
skeletal muscle,12 evidence suggests that vitamin D metab-
olites are also implicated in skeletal muscle function and 
repair.13–16 Clinical trials undertaken in geriatric and 
clinical populations13 17 18 have established a potential 
link between vitamin D sufficiency, as assessed by circu-
lating total 25-hydroxyvitamin D (25(OH)D) and physical 
performance including measures such as balance, gait 
speed, hand grip and lower limb strength, highlighting 
the role of vitamin D status in muscle function. In support 
of these findings, longitudinal studies undertaken in 
vitamin D-deficient adults showed that correcting vitamin 
D deficiency with use of dietary supplement interventions 
resulted in improved muscle mitochondrial function, 
associated with an improvement in symptoms of myop-
athy and fatigue.19 The potential importance of vitamin 
D signalling is also highlighted by the ability of vitamin 
D signalling to modulate the activation of nuclear factor 
kappa B, a pleiotropic transcription factor involved in 
many biological and pathological processes including 
inflammation and immunity.20 Indeed, 1,25(OH)2D is 
also proposed to be a potent regulator of innate and 
acquired immunity.21
Due to the pleiotropic functions of vitamin D metab-
olites, the sterols have been examined in the context of 
disease and have consequently been correlated with a 
number of pathologies including tuberculosis, motor 
neuron and autoimmune diseases22–24 and in clinical 
populations including patients with osteomalacia, who 
display skeletal muscle myopathy and weakness that 
is responsive to vitamin D supplementation.25 Despite 
non-scientific media interest, few data exist examining 
circulating concentration of vitamin D metabolites in 
patients with CFS/ME. There has been only one retro-
spective study that suggests that patients with CFS/ME 
may experience suboptimal concentrations of circulating 
25(OH)D,26 hence the assumption that low circulating 
25(OH)D concentrations in CFS/ME may be respon-
sible for the altered immune profiles27 28 and fatigue. The 
objective of the current study was to determine whether 
vitamin D status, as assessed by circulating 25(OH)D, is a 
contributing factor to the pathophysiology of CFS/ME. 
To meet this objective, we investigated whether CFS/




Male and female patients with CFS/ME (n=92) were 
recruited through the regional National Health Service 
CFS services based in Liverpool at the Royal Liverpool 
and Broadgreen University Hospital Trust, Merseyside, 
UK. All patients were newly diagnosed by clinicians 
in accordance with the recommended National Insti-
tute for Health and Care Excellence (NICE) guidelines 
200729 and covered a wide spectrum of disease severity 
from mild, through to moderate and severe CFS/ME. All 
patients routinely completed the Chalder Fatigue Ques-
tionnaire. Bed-bound/non-ambulatory patients were 
not enrolled in the study. Ninety-four age-matched and 
sex-matched healthy controls (HCs) (with exclusions 
of smoking or substance misuse, medication including 
anti-inflammatory medication or non-ambulatory 
subjects) were also recruited through local advertisement 
in the city of Liverpool and during CFS/ME recruitment 
sessions and served as the control group. This group also 
completed the Chalder Fatigue Questionnaire. Sample 
size was determined according to power calculations to 
allow for a significant difference in serum 25(OH)D to 
be detected between the two cohorts. Individuals were 
excluded from the study if they smoked, had a history 
of substance misuse or had any underlying inflammato-
ry-based medical conditions or treatments. This study 
conformed to the standards set by the Declaration of 
Helsinki, and the procedures were approved by the local 
University of Liverpool peer review committee and multi-
centre research ethics committee. All participants gave 
informed written consent for their participation.
sample collection
For the analysis of vitamin D metabolites including 
25(OH)D2 and 25(OH)D3, participants provided a 
venous blood sample collected from the antecubital vein 
into two serum separator (4.7 mL) vacutainers. Blood 
samples were incubated for 45 min at room temperature 
to induce clotting, followed by centrifugation at 1500 g 
for 15 min at 4°C. Serum was aspirated from the samples 
and stored at −80°C until analysis. All serum samples were 
given an anonymous coded identification number, which 
was sequentially generated by the study team.
Analysis of vitamin D
Vitamin D metabolites 25(OH)D2 and 25(OH)D3 
were analysed as previously described.8 25(OH)D2 and 
25(OH)D3 were extracted from serum samples, following 
zinc sulfate protein precipitation, using Isolute C18 
solid phase extraction cartridges. Potential interfering 
compounds were removed by initial elution with 50% 
methanol followed by elution of the vitamins using 10% 
tetrahydrofuran in acetonitrile. Dried extracts were 
reconstituted prior to injection into a high-performance 
liquid chromatography tandem mass spectrometry (LC–
MS/MS) in the multiple reaction mode. The multiple 
reaction mode transitions (m/z) used were 413.2>395.3, 
401.1>383.3 and 407.5>107.2 for 25(OH)D2 and 25(OH)
D3, and hexadeuterated (OH)D3, respectively. The assay 
was validated against published acceptance criteria (FDA 
2001). Assay sensitivity was determined by the lower limit 
of quantification: 25(OH)D3=2.5 nmol/L and 25(OH)
 3Earl KE, et al. BMJ Open 2017;0:e015296. doi:10.1136/bmjopen-2016-015296
Open Access
Table 1 Baseline characteristics of study participants
HC CFS/ME
Women (n) 58 66
Men (n) 36 26
Caucasian (n) 89 91
Age (years) 33±10 40±10
BMI (kg/m2) 24.4±3.4 26.0±4.2
Illness duration (months) N/A 36±4.8
Sample acquisition 94 92
Data are presented as mean±SD unless otherwise stated.
BMI, body mass index; CFS/ME, chronic fatigue syndrome/myalgic 
encephalomyelitis; HC, healthy control.
D2=2.5 nmol/L. Coefficients of variation for the assay 
were 10% across a working range of 2.5–625 nmol/L for 
both 25(OH)D2 and 25(OH)D3.
Intra-assay precision was assessed by running quality 
control materials (Chromsystems Instruments and Chem-
icals, Gräfelfing, Germany) and commercially bought 
material (calf serum) 10 times within a single run, 
and separately over 15 runs for interassay assessment. 
Extraction recovery was assessed by determining the 
amount of vitamin D3/D2 recovered from the amount 
spiked prior to extraction. The percentage recovery 
was calculated by the measured value against the sum 
of endogenous value and spiking concentration. Spiked 
recovery is determined by adding known quantity of 
25(OH)D3/D2 to serum samples with different concen-
trations of endogenous 25(OH)D. MassCheck calibration 
materials and controls are traceable against NIST 972 
reference material.
The LC–MS/MS method used in the present study has 
previously been validated against other commercially 
available assays and is regarded as the most valid and reli-
able technique for the assessment of vitamin D metabo-
lites including 25(OH)D2 and 25(OH)D3.
30
Dietary/supplement analyses
Structured open-ended food/supplement diaries were 
provided to all patients and control. All participants were 
informed on how to complete the food record. The diary 
also contained a written example for reference. During 
a 7-day period, all consumed foods/drinks and supple-
ments had to be reported with notification of time of 
consumption, estimated consumed quantity expressed as 
a household measure, unit or weight, specification and if 
present, a brand name. Food diaries were analysed using 
WinDiets Research Version (2010) software, written by Dr 
Alan Wise, The Robert Gordon University, Aberdeen.
Patient involvement
The development of both the study research question 
and outcome measures took into careful consideration 
the needs and impact on the patient cohort particularly 
given the highly sensitive nature of this group. Careful 
consideration was taken over the execution of study visits 
and the impact of the study protocol and sample collec-
tion. The study was designed to reduce the impact and 
disturbance to the patient’s condition. Senior specialists 
in CFS/ME provided advice with regard to study design. 
No patients were involved in setting the research ques-
tion, nor were they involved in developing plans for 
design or implementation of the study. No patients were 
asked to advise on interpretation or writing up of results. 
Registered patient support groups within the local area 
of Merseyside including patients with CFS/ME and their 
carers provided support in the recruitment of patients 
into the study through the dissemination of study infor-
mation and recruitment. Results will be disseminated by 
presentation to local and national research and patient 
groups.
statistics
Data are presented as mean±SD throughout. The sample 
distribution was determined using the Pearson’s coef-
ficient indicating a predominantly parametric distribu-
tion. Single comparisons between two groups of normally 
distributed data were undertaken using independent 
Student’s t-tests. For multiple comparison analyses to 
examine the effect of season, one-way analysis of variance 
followed by post hoc Tukey’s LSD test was used. A p value 
<0.05 was considered to be statistically significant. SPSS 
V.22 was used to analyse all data. Figures were constructed 
with GraphPad Prism V.6.
results
Details of the study population are presented in table 1. 
Epidemiological studies have reported that the preva-
lence of CFS/ME is significantly higher in women than in 
men31 and the majority of patients with CFS/ME who took 
part in the present study were female (66 women and 26 
men). Body mass index analyses revealed no significant 
differences between patients with CFS/ME and HCs (26.0 
and 24.4 kg/m2, respectively) (table 1). Average duration 
of illness in the patients with CFS/ME was 36±4.8 months.
Total serum 25(OH)D was assessed by measuring the 
sum of 25(OH)D2 and 25(OH)D3 metabolites. Circulating 
25(OH)D2 was undetectable in 86% and 89% of CFS/
ME and HC individuals, respectively (data not shown). 
Undetectable concentrations of circulating 25(OH)D2 
in human samples have previously been reported in a 
number of studies.32 Total serum 25(OH)D concentra-
tion was significantly higher (p=0.001) in patients with 
CFS/ME compared with HCs (60.2 and 47.3 nmol/L, 
respectively) (figure 1A).
To further examine the observed difference in vitamin 
D status between patients with CFS/ME and HC, the 
effects of seasonal variation in circulating concentra-
tions of 25(OH)D were determined. Statistical analyses 
revealed a significant interaction between group and 
season for total serum 25(OH)D (figure 1B). Patients with 
CFS/ME demonstrated significantly higher (p=0.01) total 
serum 25(OH)D concentrations during the autumn and 
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Table 2 Dietary/supplement assessment of average 
vitamin D intake by patients with chronic fatigue syndrome/
myalgic encephalomyelitis (CFS/ME) compared with healthy 
control (HC) individuals
HC CFS/ME p Value
Average vitamin D intake—
diet (µg/day)
2.9±2.1 2.4±1.6 0.6
Average vitamin D intake—
supplements (µg/day)
0.6±1.7 4.9±9.7 0.05
Data are presented as mean ±SD.
Figure 1 (A) Distribution plots of individual circulating total 25(OH)D concentrations (nmol/L) assessed in patients with chronic 
fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and healthy controls (HCs) using liquid chromatography tandem mass 
spectrometry. *p<0.05 compared with values from the HC. (B) Total serum 25(OH)D concentration in patients with CFS/ME and 
HCs recruited during the spring–summer months (1 March31 August) and autumn–winter months (1 September–28 February). 
*p<0.05 compared with values from the HC group recruited during autumn/winter. #p<0.05 compared with values from the HC 
group recruited during the Spring/Summer months. Close grey circles denote HC and closed black boxes denote CFS/ME. Each 
data point refers to an individual participant. Solid black bars represent the mean±SD.
winter months (autumn/winter) compared with HC indi-
viduals (59.1±24.1 and 45.6±25.9 nmol/L, respectively), 
with no significant difference evident during the spring 
and summer months (spring/summer) (figure 1B). 
The average total serum 25(OH)D concentration from 
HCs recruited during spring/summer tended to be 
~30% higher (p=0.08). Although this did not reach statis-
tical significance in comparison to individuals recruited 
in autumn/winter (60.2±22.7 and 45.6±25.9 nmol/L, 
respectively), (figure 1B), these data are in agreement 
with previous clinical studies demonstrating that vitamin 
D status varies seasonally, with concentrations of 25(OH)
D increasing in spring and peaking at summer.33
The higher total serum 25(OH)D concentrations in 
patients with CFS/ME during the autumn/winter months 
is likely to be a result of increased vitamin D intake. To 
address this possibility, dietary/supplement assessment 
of vitamin D intake from both diet and in the form of 
supplements was undertaken although, due to compli-
ance issues, these data were only provided by 21 HCs 
and 24 patients with CFS/ME (table 2). Dietary intake 
of vitamin D did not differ significantly between patients 
with CFS/ME and HC individuals. However, more patients 
with CFS/ME reported multivitamin supplement and/or 
vitamin D supplement consumption than HCs. Because 
of the increased use of supplements by patients with CFS/
ME, the cohort of patients with CFS/ME showed higher 
(p=0.05) average vitamin D intake through use of supple-
ments compared with the cohort of HCs (4.9±9.7 and 
0.6±1.7 µg/day, respectively) (table 2). When we limit 
the analysis to those individuals taking vitamin D supple-
ments, the average intake for HCs was 4.2 µg/day 
compared with 14.1 µg/day for patients with CFS/ME. In 
addition, analysis revealed no differences in total serum 
25(OH)D in the patients with CFS/ME compared with 
HC individuals reporting no vitamin D supplement intake 
(figure 2). Overall these findings suggest that the higher 
serum 25(OH)D concentrations observed in patients 
with CFS/ME during the autumn and winter months was 
likely to be due to increased vitamin D intake through 
use of supplements. Individuals with CFS/ME reported 
significantly higher levels of fatigue than the HC group 
in the Chalder Fatigue Questionnaire; a widely used and 
validated health questionnaire (data not shown in detail). 
To assess whether serum concentrations of total 25(OH)
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Figure 2 Total serum 25(OH)D concentration in patients 
with chronic fatigue syndrome/myalgic encephalomyelitis 
(CFS/ME) and healthy controls (HCs) who reported no 
intake of vitamin D supplements. Each data point refers 
to an individual participant. Solid black bars represent the 
mean±SD. Figure 3 Chalder Fatigue Scores in patients with chronic 
fatigue syndrome/myalgic encephalomyelitis (CFS/ME). 
25(OH)D values from the CFS/ME group were ordered from 
lowest to highest and split equally into an upper and lower 
range. Each data point refers to an individual participant. 
Solid black bars represent the mean±SD.
D were a contributing factor to the level of fatigue in 
CFS/ME, 25(OH)D values from the CFS/ME group were 
ordered from lowest to highest and split equally into an 
upper and lower range (figure 3). The data presented 
show no evidence of a difference in mean or distribution 
of Chalder Fatigue Questionnaire Score between the two 
groups and so suggest that total serum 25(OH)D concen-
tration does not appear to be a major contributing factor 
to the level of fatigue in patients with CFS/ME.
DIscussIOn
The present findings suggest that patients with CFS/ME 
do not exhibit insufficient concentrations of circulating 
total 25(OH)D, but the values are significantly higher 
compared with HCs. The average concentration of serum 
total 25(OH)D in patients with CFS/ME was 60.2 nmol/L 
and was greater than the sufficient cut-off of ≥50 nmol/L 
set by the UK and US Institutes of Health.33 Scores from the 
Chalder Questionnaire revealed no differences between 
individuals with CFS/ME with high or low total 25(OH)
D concentrations. This finding implies that vitamin 
D deficiency is not a major contributing factor to the 
pathophysiology of CFS/ME. The data from the present 
study further demonstrated that the average concen-
tration of circulating total 25(OH)D in the HC group 
was lower (47.3 nmol/L) than the suggested sufficient 
concentrations (>50 nmol/L), in agreement with recent 
reports from the NICE that insufficient serum vitamin D 
concentrations are common in the UK. The present find-
ings suggest individuals with CFS/ME have higher total 
25(OH)D than HCs, particularly in the spring/summer 
months, due to the consumption of vitamin D supple-
ments. In contrast, further analysis revealed no significant 
differences in total 25(OH)D between individuals with 
CFS/ME and HCs who reported no supplement intake. 
Overall these findings imply that the higher total 25(OH)
D in the CFS/ME group is likely attributed to the overall 
higher supplemental vitamin D intake.
Individuals with circulating 25(OH)D concentra-
tions >50 nmol/L are likely to have sufficient concentra-
tions to maintain normal biological functions. However, 
concentrations between 30 and 50 nmol/L are considered 
to be insufficient and <25 nmol/L are likely to lead to the 
pathology of muscle and bone disorders such as osteo-
malacia and osteoporosis and to reduce overall health.34 
Previous research has been undertaken to determine 
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changes in total 25(OH)D throughout the year as the 
intensity and hours of sunlight change.35 The current 
study further sought to examine the changes that occur in 
vitamin D status throughout the year in both patients with 
CFS/ME and age-matched/sex-matched HC individuals. 
Seasonal variation analyses revealed that HC individuals 
recruited during autumn/winter exhibited insufficient 
levels of circulating 25(OH)D (<50 nmol/L) with concen-
trations rising significantly to normal values (>50 nmol/L) 
in individuals recruited during spring/summer. In 
contrast, there was a lack of difference in circulating 
25(OH)D between autumn/winter and spring/summer 
in patients with CFS/ME. Data showed an ~50% reduc-
tion in vitamin D supplement intake in the patient 
cohort recruited during the summer months. Caution is 
required when interpreting these findings since the study 
is cross-sectional and so represents different patients and 
these changes in supplement intake did not reach signif-
icance (data not shown), but may suggest that patients 
with CFS/ME reduce their supplement intake of vitamin 
D during the summer months. Alternatively, the patients 
may not have been exposed to increased sunlight during 
the summer months due to reduced mobility and being 
housebound as a result of the symptoms associated with 
CFS/ME. The observed suboptimal circulating 25(OH)D 
concentration in healthy individuals during the autumn 
and winter months was likely due to insufficient vitamin 
D intake and/or lack of adequate exposure to sunlight.13 
The higher prevalence of sufficient 25(OH)D concentra-
tions observed in patients with CFS/ME during autumn/
winter were associated with higher vitamin D intake 
through use of supplements when compared with HCs.
Patients with CFS/ME suffer from a wide range of 
debilitating symptoms and, depending on these symp-
toms, there may be reduction in exposure to the sun. 
The current study included patients across the disease 
spectrum from mild severity through to moderate and 
severe, although excluding bed-bound/non-ambulatory 
patients. As a result, it is plausible to assume that there 
may be a subgroup of patients with CFS/ME, who may be 
at greater risk for deficiency. One limitation of the present 
work was that the majority of participants who took part 
in the study, including CFS/ME and HC volunteers, were 
Caucasians who lived in the North-West of England hence 
the findings from the present study might not reflect all 
CFS/ME and HC populations. It is noteworthy to mention 
that there is evidence that vitamin D metabolism varies in 
different ethnic groups.34 Future studies comparing CFS/
ME including non-ambulatory patients and HC individ-
uals from different origin, race and disease duration are 
also warranted. A further limitation to the study was that 
only the main marker of vitamin D status, that is, 25(OH)
D, was measured. It has recently been shown that there is 
a need to assess all of the vitamin D metabolites.35 It may 
be more appropriate to measure the amount of serum-
free and bioavailable 25(OH)D as a predictor of vitamin 
D status than serum total 25(OH)D, while controlling 
for vitamin D binding protein phenotype.36 Future 
studies assessing these aspects of vitamin D metabolism in 
patients with CFS/ME are warranted.
In conclusion, patients with CFS/ME do not exhibit 
insufficient concentrations of circulating 25(OH)D3 at 
any time of the year. Given that this cohort of patients 
with CFS/ME clearly displays symptoms, regardless of 
serum 25(OH)D concentration, these data indicate that 
vitamin D status may not be a major contributing factor to 
the pathophysiology of patient with CFS/ME symptoms, 
although further analyses of those individuals with lower 
circulating 25(OH)D and more detailed investigation into 
vitamin D metabolism is still warranted. Current health 
guidelines in the UK state supplementation of vitamin D 
should be recommended to individuals with increased 
risk of deficiency and the findings from the present study 
suggest, in agreement with other studies, that a signifi-
cant percentage of healthy individuals exhibit insuffi-
cient concentrations of circulating vitamin D during the 
autumn and winter months. The current findings do not 
support the notion that vitamin D concentration contrib-
utes to the continuing symptoms of CFS/ME. However, 
it may be important for patients with CFS/ME to supple-
ment with vitamin D during the winter months as it is 
well documented that non-supplemented individuals may 
typically present with insufficient serum 25(OH)D during 
the winter season.
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